Effect of remimazolam on intraoperative hemodynamic stability in patients undergoing cerebrovascular bypass surgery: a prospective randomized controlled trial
Korean Journal of Anesthesiology · 2025
DOI: 10.4097/kja.24538 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Korean Journal of Anesthesiology, 2025. Verfasst von Chang-Hoon Koo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. Hauptthemen laut MEDLINE: Hemodynamics, Benzodiazepines. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Seoul National University Bundang Hospital.
Abstract (Originalsprache)
Background
Maintenance of stable blood pressure (BP) during cerebrovascular bypass surgery is crucial to prevent cerebral ischemia. We compared the effect of remimazolam anesthesia with that of propofol-induced and desflurane-maintained anesthesia on intraoperative hemodynamic stability and the need for vasoactive agents in patients undergoing cerebrovascular bypass surgery.
Methods
Sixty-five patients were randomized into remimazolam (n = 31, remimazolam-based intravenous anesthesia) and control groups (n = 34, propofol-induced and desflurane-maintained anesthesia). The primary outcome was the occurrence of intraoperative hypotension. The secondary outcomes included hypotension duration, lowest mean BP (MBP), generalized average real variability (ARV) of MBP, and consumption of phenylephrine, norepinephrine, or remifentanil.
Results
Occurrence rate and duration of hypotension were significantly lower in the remimazolam group (38.7% vs. 73.5%, P = 0.005; 0 [0, 10] vs. 7.5 [1.25, 25] min, P = 0.008). Remimazolam also showed better outcomes for lowest MBP (78 [73, 84] vs. 69.5 [66.25, 75.8] mmHg, P < 0.001) and generalized ARV of MBP (1.42 ± 0.49 vs. 1.66 ± 0.52 mmHg/min, P = 0.036). The remimazolam group required less phenylephrine (20 [0, 65] vs. 100 [60, 130] μg, P < 0.001), less norepinephrine (162 [0, 365.5] vs. 1335 [998.5, 1637.5] μg, P < 0.001), and more remifentanil (1750 [1454.5, 2184.5] vs. 531 [431, 746.5] μg, P < 0.001) than the control group.
Conclusions
Remimazolam anesthesia may provide better hemodynamic stability during cerebrovascular bypass surgery than propofol-induced and desflurane-maintained anesthesia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
- Department of Anesthesiology and Pain Medicine, Seoul National University College of Medicine, Seoul, Korea.
- Department of Neurosurgery, Seoul National University Bundang Hospital, Seongnam, Korea.
- Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea.
Förderung
- Seoul National University Bundang Hospital
Zitieren
APA
Koo, C. H., Lee, S. U., Kim, H. G., Lee, S., Bae, Y. K., Oh, A. Y., Jeon, Y. T., & Ryu, J. H. (2025). Effect of remimazolam on intraoperative hemodynamic stability in patients undergoing cerebrovascular bypass surgery: a prospective randomized controlled trial. Korean Journal of Anesthesiology. https://doi.org/10.4097/kja.24538
Vancouver
Koo CH, Lee SU, Kim HG, Lee S, Bae YK, Oh AY, et al. Effect of remimazolam on intraoperative hemodynamic stability in patients undergoing cerebrovascular bypass surgery: a prospective randomized controlled trial. Korean Journal of Anesthesiology. 2025. doi:10.4097/kja.24538
BibTeX
@article{Koo2025,
author = {Koo, Chang-Hoon and Lee, Si Un and Kim, Hyeong-Geun and Lee, Soowon and Bae, Yu Kyung and Oh, Ah-Young and Jeon, Young-Tae and Ryu, Jung-Hee},
title = {Effect of remimazolam on intraoperative hemodynamic stability in patients undergoing cerebrovascular bypass surgery: a prospective randomized controlled trial},
journal = {Korean Journal of Anesthesiology},
year = {2025},
doi = {10.4097/kja.24538}
}
EUVIMED